AUDREY LASTRA: Open Payments
NPI 1104105600 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,625 in 122 payments from 21 companies in 2025. Trend: 2023 $2,058 · 2024 $3,930 · 2025 $5,625
Food & beverage: $3,988Consulting: $1,560Education: $77
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 13 | $1,995 |
| Madrigal Pharmaceuticals | 7 | $686 |
| ABBVIE INC. | 26 | $501 |
| Phathom Pharmaceuticals, Inc. | 14 | $427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $330 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $317 |
| Ardelyx, Inc. | 11 | $309 |
| Regeneron Healthcare Solutions, Inc. | 4 | $198 |
| Novo Nordisk Inc | 2 | $156 |
| GENZYME CORPORATION | 6 | $142 |
Products named: TREMFYA, REZDIFFRA, VOQUEZNA, DUPIXENT, IBSRELA, XIFAXAN, ENTYVIO, Wegovy.
Industry payments across CT — which companies pay providers there.
